A review of six placebo-managed clinical trials with one,134 total participants concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) were being related to a higher common enhancement on the Ashworth scale for spasticity in multiple sclerosis individuals in contrast with placebo, although this did not achieve statistical significance. We only use https://creightonc851xrn1.wiki-promo.com/user